Petek Donmez, MD
Internal Medicine · Rockville, MDNPI 1609953116
Payments from drug & device makers
Across 434 payments — averaging $15.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- AstraZeneca$641
- Novo Nordisk$503
- Pfizer$380
- Lilly USA, LLC$213
- GSK$207
- plus $2K from 30 others
What the payments were for
- Food & beverage$6,43398%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 194 | $2,696 |
| AstraZeneca | 36 | $641 |
| Novo Nordisk | 33 | $503 |
| Pfizer | 30 | $380 |
| Lilly USA, LLC | 10 | $213 |
| GSK | 11 | $207 |
| Amgen(2 entities) | 11 | $193 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $190 |
| Astellas Pharma US Inc | 4 | $141 |
| Biohaven Pharmaceutical Holding Company Ltd. | 19 | $140 |
| Novartis | 7 | $113 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $88 |
| Exact Sciences | 4 | $78 |
| Teva Pharmaceuticals USA, Inc. | 5 | $75 |
| Biohaven Pharmaceuticals, Inc. | 5 | $74 |
| Merck | 5 | $71 |
| Redhill Biopharma Inc. | 4 | $69 |
| Boehringer Ingelheim | 5 | $68 |
| Kowa Pharmaceuticals America, Inc. | 4 | $64 |
| Ironwood Pharmaceuticals, Inc | 4 | $56 |
| Ironshore Pharmaceuticals Inc. | 2 | $50 |
| Botanix SB Inc | 2 | $48 |
| Otsuka America Pharmaceutical, Inc. | 3 | $43 |
| Abbott | 2 | $41 |
| Johnson & Johnson | 2 | $38 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| Supernus Pharmaceuticals, Inc. | 2 | $31 |
| Esperion Therapeutics, Inc. | 1 | $26 |
| Eisai Inc. | 2 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Dermavant Sciences, Inc. | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 2 | $21 |
| Arcutis Biotherapeutics, Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $13 |
How this compares
$6,533 in reported general payments places this provider in the 90th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 175 | $227,035 |
| FarxigaDapagliflozin Propanediol | 61 | $70,640 |
| EliquisApixaban | 54 | $59,107 |
| JanuviaSitagliptin Phosphate | 37 | $52,224 |
| MounjaroTirzepatide | 41 | $37,110 |
| Wellbutrin XlBupropion Hcl | 14 | $34,575 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $31,697 |
| LinzessLinaclotide | 22 | $23,907 |
| JardianceEmpagliflozin | 13 | $17,062 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 18 | $12,643 |
| MyrbetriqMirabegron | 12 | $9,718 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $6,055 |
| Memantine Hcl ErMemantine Hcl | 18 | $5,948 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,641 |
| PaxlovidNirmatrelvir/Ritonavir | 24 | $4,222 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $503 | $227,035175 claims |
| AstraZenecaFarxiga | $641 | $70,64061 claims |
| MerckJanuvia, Janumet Xr | $71 | $64,86855 claims |
| PfizerEliquis, Paxlovid | $380 | $63,32878 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $207 | $37,75243 claims |
| Lilly USA, LLCMounjaro | $213 | $37,11041 claims |
| AbbVieLinzess, Synthroid | $2,696 | $26,91558 claims |
| Boehringer IngelheimJardiance | $68 | $17,06213 claims |
| Astellas Pharma US IncMyrbetriq | $141 | $9,71812 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $88 | $4,64112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Rockville
- Shishir KhetanRockville$52.1M
- Jonathan CohenRockville$5M
- Rahul PatelRockville$2.8M
- Alan PollackRockville$2.1M
- Ravi PassiRockville$1.6M
- Padmaja MuthiahRockville$302K
- Ira BergerRockville$228K
- Michael SauriRockville$214K
- David CharlesRockville$171K
- Steven GellerElkridge$15.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.